Oruka Therapeutics, Inc.
Clinical trials sponsored by Oruka Therapeutics, Inc., explained in plain language.
-
Psoriasis drug ORKA-001 tested for long-term safety in extension trial
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug ORKA-001 for adults with moderate-to-severe plaque psoriasis. Participants must have completed a previous Oruka Therapeutics study. The main goal is to track side effects, while also checking how well the drug…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:54 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests an experimental drug called ORKA-001 in 160 adults with moderate-to-severe plaque psoriasis. Participants receive either the drug or a placebo to see if it can clear skin lesions. The main goal is to measure complete skin clearance after 16 weeks of treatment.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated May 26, 2026 11:55 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a new medicine called ORKA-002 for people with moderate-to-severe plaque psoriasis. About 160 adults will receive either the drug or a placebo to see if it can clear skin and reduce symptoms. The goal is to find the best dose and check for side effects.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC